Authors

Ioana Mădălina Zota*, Maria Magdalena Leon Constanti*, Cristian Stătescu*, Radu Andy Sascău*, Mihai Roca*,#, Radu Sebastian Gavril*, Teodor Flaviu Vasilcu*,  Daniela Boișteanu**, Cojocaru Elena***,#, Alexandra Maștaleru*, Ovidiu Mitu*, Florin Mitu*

Departments

*Department of Medical Specialties (I), Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 16 University Street, Iasi 700115, Romania - **Department of Medical Specialties (III), Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy16 University Street, Iasi 700115, Romania - ***Department of Morphofunctional Sciences (I), Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 16 University Street, Iasi 700115, Romania

Abstract

Objective: This study aims to highlight the benefit of CPAP therapy in patients with cardio-metabolic comorbidities (hypertension, diabetes, obesity) assessed in a cardiovascular rehabilitation clinic. 

Methods: We performed a prospective study that included 33 patients newly-diagnosed with moderate up to severe OSA, who were evaluated before and after 2 months of CPAP therapy.

Results: Male sex, abdominal obesity, hypertension, impaired glucose and lipid metabolism were main features in our OSA group. OSA severity was correlated to heart rate, inflammation markers and total cholesterol. After 2 months, CPAP induced significant improvement in weight, abdominal circumference, resting heart rate, total cholesterol and glycated hemoglobin. CPAP was also associated with improved results in the Euro Quality of Life and Epworth questionnaires.

Conclusion: Noninvasive ventilation is associated with improved weight status, total cholesterol, HbA1c levels and quality of life, but OSA therapy is limited by poor device tolerance and suboptimal CPAP use.

Keywords

Obstructive sleep apnea, hypertension, metabolic syndrome, CPAP.

DOI:

10.19193/0393-6384_2020_3_309